research Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study
Dupilumab effectively reduces symptoms of prurigo nodularis and is safe for long-term use.
Search
for
Sort by
Research
240-270 / 1000+ results
research Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
research Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
research Tebentafusp-tebn (Kimmtra®)
Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
research Assessing medication use patterns among patients with polycystic ovary syndrome at a tertiary care teaching hospital in South Korea: A retrospective study
Most patients with PCOS were prescribed medroxyprogesterone acetate or oral contraceptives, with some experiencing side effects or needing prescription changes.
research From Hair Loss to Vision Loss: Minoxidil-Associated CRVO in a Young Female
A young woman developed a vision-threatening eye condition after using minoxidil for hair loss, which improved when she stopped the medication.
research Author response: Effects of lifelong testosterone exposure on health and disease using Mendelian randomization
Long-term high testosterone levels can improve bone density and reduce body fat but may increase the risk of prostate cancer and high blood pressure.
research Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil: A randomized, double-blind, placebo-controlled clinical trial
Sublingual minoxidil safely increases hair growth in transgender people on testosterone therapy.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.
research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial
Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
research Budesonide for maintenance of remission in Crohn's disease
Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
research Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014)
Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
research Dupilumab in Inflammatory Skin Diseases: A Systematic Review
Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.
research Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
research A randomized, controlled clinical trial of autologous stromal vascular fraction cells transplantation to promote mechanical stretch-induced skin regeneration
SVF cell transplantation improves skin regeneration safely.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
research Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia
Taking tadalafil and finasteride together is safe and effective for treating urinary symptoms and erectile dysfunction in men with enlarged prostates.
research Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial
ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
research The Effects of Lower vs Higher Cell Number of Platelet-Rich Plasma (PRP) on Hair Density and Diameter in Androgenetic Alopecia (AGA): A Randomized, Double-Blinded, Placebo, Parallel-Group Half-Scalp IRB-Approved Study.
Higher cell number PRP improves hair density and diameter more than lower cell number PRP.
research Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population
The treatment effectively reduces menopausal symptoms and is well tolerated.
research Therapeutic Potential of Gynostemma pentaphyllum Extract for Hair Health Enhancement: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Gynostemma pentaphyllum extract improves hair elasticity, density, and thickness safely.
research Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
Ritlecitinib effectively regrows hair in severe alopecia areata, especially in adolescents.
research Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
Baricitinib is effective and safe for treating severe alopecia areata.